[
  {
    "question": "Stroke and diagnosed with acute ischemic stroke, patient undergone work up and her vessels imaging showed atherosclerotic disease however no critical stenosis, ECHO is normal except for an EF of 55%, 8-hour Holter did not show any arrhythmia, HBA1C and lipid profile was accepted. What is the most likely mechanism of her stroke?",
    "option_a": "embolism (most likely it wasn\u2019t clear)",
    "option_b": "hypoperfusion",
    "option_c": "vessel stenosis",
    "option_d": "thrombosis",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Acute ischemic stroke has several potential mechanisms, including embolic, thrombotic (in situ), hypoperfusion, or due to severe vessel stenosis. When routine investigations fail to reveal a high-grade source, the etiology may be classified as embolic or cryptogenic. Embolic strokes occur when an embolus, originating from the heart or another source, occludes a cerebral artery. In some patients, particularly those who lack identifiable causes like atrial fibrillation, high-grade arterial stenosis, or cardiac thrombi, the stroke is considered embolic in nature\u2014often termed an embolic stroke of undetermined source (ESUS). The described patient has evidence of atherosclerotic disease but no critical stenosis, a normal echocardiogram with preserved ejection fraction, and no arrhythmias on prolonged monitoring. These findings support the likelihood of an embolic event where the source remains unclear, fitting the profile of a cryptogenic embolism. A comprehensive evaluation includes vascular imaging (Doppler ultrasound, CT/MR angiography) to look for significant stenoses, cardiac investigations (echocardiography, Holter monitoring) to search for embolic sources, and laboratory assessments for thrombophilia. Differential diagnoses include hypoperfusion-related strokes (which typically occur in watershed zones) and in situ thrombosis over a ruptured plaque, but the workup in this case points away from these causes. Current guidelines recommend antiplatelet therapy (e.g., aspirin) as the mainstay for secondary prevention in ESUS, along with aggressive management of vascular risk factors. Although clinical trials have investigated the role of direct oral anticoagulants for ESUS, antiplatelet therapy remains standard unless a clear embolic source is subsequently identified. In pregnant or lactating patients, low-dose aspirin is generally considered safe for stroke prevention. Option A (embolic mechanism) is most consistent with the workup findings and the clinical scenario (i.e., an embolic stroke of undetermined source). Option B (hypoperfusion) usually produces watershed infarcts and is associated with systemic hypotension. Option C (vessel stenosis) is less likely given the imaging did not reveal critical stenosis, and Option D (thrombosis from a local clot) is less favored when embolic sources are more likely even if occult. 1. ESUS should be considered when a stroke appears embolic but no high\u2010grade stenosis or cardiac source is identified after a comprehensive evaluation. 2. Management of ESUS focuses on secondary prevention with antiplatelet therapy and risk factor modification. Recent clinical trials have explored the role of anticoagulants in ESUS, but current guidelines continue to recommend antiplatelet agents as first-line therapy. Ongoing research may eventually refine the approach, especially in patients with subtle prothrombotic tendencies.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "short scenario with attached image of NCS showing drop of amplitude:",
    "option_a": "Conduction block",
    "option_b": "Temporal dispersion",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Nerve conduction studies (NCS) evaluate the integrity of peripheral nerves. A key parameter is the amplitude of the compound muscle action potential (CMAP). A significant drop in amplitude across a segment of the nerve suggests that many axons are not contributing normally, often because of a conduction block. Conduction block occurs when demyelination or other pathologic processes prevent the consistent propagation of the nerve impulse across a segment of a nerve. This results in a reduction of the recorded CMAP amplitude distal to the lesion. Temporal dispersion, on the other hand, is characterized by prolonged duration of the CMAP due to variable slowing among individual nerve fibers, which tends to smear out the waveform rather than simply reduce its amplitude. In conditions such as multifocal motor neuropathy or in some forms of demyelinating neuropathies, conduction block is a key electrophysiological finding that correlates with segmental demyelination. The patient\u2019s nerve conduction study demonstrating a drop in amplitude is highly suggestive of a conduction block. Interpretation of NCS involves comparing amplitude, conduction velocity, and waveform morphology. Differential considerations include temporal dispersion (which shows waveform broadening rather than isolated amplitude reduction) and axonal loss (which may also reduce amplitude but tends to affect the entire nerve rather than in a focal block). Management of conditions showing conduction block depends on the underlying cause. In multifocal motor neuropathy, for example, treatment with intravenous immunoglobulin (IVIg) is first-line. Corticosteroids are typically ineffective or may worsen the condition. In pregnancy or lactation, IVIg is generally considered safe and is often used as a treatment modality for immune-mediated neuropathies. Option A (Conduction block) is correct since the drop in amplitude on NCS is most indicative of this phenomenon. Option B (Temporal dispersion) would be characterized by a waveform with increased duration and not solely a drop in amplitude. Options C and D are not provided, making them non-applicable. 1. A focal drop in CMAP amplitude with preserved conduction velocity across other segments is highly suggestive of a conduction block. 2. Differentiating conduction block from temporal dispersion is essential as the management and prognosis of demyelinating versus axonal neuropathies differ. Recent electrophysiological studies and guidelines continue to stress the importance of distinguishing conduction block from other NCS abnormalities. In immune-mediated neuropathies, early identification of conduction block facilitates timely treatment, with IVIg being supported by robust evidence and considered safe even during pregnancy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "36-year-old patient who present with memory complaint and visual-spatial defect what is the responsible gene (Alzheimer scenario):",
    "option_a": "TREM",
    "option_b": "ubiquitin",
    "option_c": "EPO4",
    "option_d": "APP",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Alzheimer\u2019s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss, changes in language and visuospatial function, and other cognitive deficits. In familial (early\u2010onset) AD, specific gene mutations such as those in the amyloid precursor protein (APP) gene drive the pathology. This question, describing a 36\u2010year\u2010old with memory and visuospatial complaints, points toward an early-onset Alzheimer\u2019s picture where mutations in the APP gene are implicated. Mutations in the APP gene result in abnormal processing of the amyloid precursor protein, leading to an overproduction or improper formation of beta-amyloid peptides. These peptides aggregate extracellularly into plaques which, along with neurofibrillary tangles composed of hyperphosphorylated tau protein, contribute to neurodegeneration. Current evidence supports that this cascade of events triggers synaptic dysfunction, oxidative stress, and neuronal death. Patients with early-onset AD typically present with cognitive deficits including memory impairment and difficulty with visuospatial tasks (which may manifest as problems with navigation or recognizing objects/people). Familial AD that involves APP mutations may present earlier than typical sporadic cases and follow an autosomal dominant inheritance pattern. The diagnosis is based on clinical evaluation, cognitive testing, and neuroimaging. Differential diagnoses include frontotemporal dementia, vascular dementia, and other neurodegenerative disorders. In familial cases, genetic testing for APP mutations (as well as presenilin 1 and 2 mutations) can support the diagnosis. Management is primarily symptomatic with cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). While there is no cure, supportive care and cognitive therapy are added. In the context of pregnancy and lactation, these medications are used with caution. Genetic counseling is recommended for familial cases. Ongoing research into beta-amyloid-targeting immunotherapies is being pursued, although these are not yet standard care. Option A (TREM) refers to genes like TREM2, which while associated with an increased risk of AD, are not typically the causative mutation in early-onset familial Alzheimer\u2019s. Option B (ubiquitin) and C (EPO4) are not implicated as causal mutations in AD. Option D (APP) is the gene directly responsible when mutated in early-onset familial Alzheimer\u2019s, making it the correct answer. 1. Early-onset familial Alzheimer\u2019s disease often involves mutations in APP, PSEN1, or PSEN2 and presents at a much younger age than sporadic AD. 2. Visuospatial deficits can be an early sign in certain variants of AD (eg, posterior cortical atrophy). Recent studies continue to elucidate the role of APP processing in AD pathogenesis, and emerging immunotherapies targeting beta-amyloid are under investigation. Genetic testing remains an important tool in diagnosing familial cases, with updated guidelines recommending counseling for affected families.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Essential tremor scenario with asthma rx;",
    "option_a": "Primidone",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Essential tremor (ET) is one of the most common movement disorders, clinically manifesting as a postural or action tremor affecting the hands and sometimes the head. First-line treatment options typically include non-selective beta-blockers (eg, propranolol) and primidone (a barbiturate). The underlying mechanism of essential tremor is not fully understood, but it is thought to involve abnormal oscillatory activity in the cerebellothalamocortical circuit. This leads to involuntary rhythmic contractions of muscles during voluntary movement or when maintaining a posture. ET typically presents with bilateral action tremor that worsens with intentional movement. When a patient also has a comorbidity such as asthma, the use of non-selective beta-blockers may exacerbate bronchospasm, thereby making primidone the preferred treatment. Diagnosis is clinical, based on history and physical examination. Differential diagnoses include Parkinson\u2019s disease (characterized by rest tremor), dystonic tremor, and tremor from hyperthyroidism. A detailed history can help distinguish ET from these conditions. For essential tremor, first-line therapy is often propranolol; however, in patients with contraindications such as asthma, primidone becomes the treatment of choice. Second-line treatments include topiramate and gabapentin. In pregnancy and lactation, primidone must be used with caution due to potential teratogenic effects; however, if needed, it may be used with careful risk-benefit analysis and under close monitoring. Option A (Primidone) is correct because it avoids the bronchoconstrictive effects seen with beta-blockers in patients with asthma. The absence of other options reinforces that primidone is the best choice for ET in the setting of asthma. 1. Essential tremor is typically an action or postural tremor and is often familial. 2. Beta-blockers are contraindicated in patients with reactive airway disease such as asthma. Recent guidelines continue to support primidone as an effective treatment for essential tremor, particularly in patients who cannot tolerate beta-blockers. Ongoing research into the cerebellothalamocortical circuits may further clarify the pathophysiological basis of ET and lead to novel therapeutic targets.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of old pt. Had stroke and became hyperactive, flight of ideas and pressured speech (mania) where will expect the lesion:",
    "option_a": "Caudate",
    "option_b": "Thalamus",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Secondary mania following a cerebrovascular accident is a recognized clinical phenomenon. It can occur when a stroke affects brain regions involved in mood regulation. This case describes an elderly patient who developed hyperactivity, flight of ideas, and pressured speech (core features of mania) after a stroke. Disruption of neural circuits, particularly within the frontal\u2013subcortical pathways, can lead to disinhibition and mood dysregulation. Lesions in the basal ganglia, especially the caudate nucleus, have been implicated in secondary mania due to their role in modulating emotional processing and executive function. Post-stroke mania is uncommon but has been associated with lesions in right hemispheric structures. The caudate nucleus plays a key role in behavioral modulation, and its injury can result in symptoms resembling a manic episode, as seen in the case. Evaluation includes a detailed neuropsychiatric assessment in the context of recent stroke. Differential diagnoses include primary bipolar disorder, medication-induced mood changes, and other post-stroke mood disorders. Neuroimaging (CT/MRI) aids in localizing the lesion and correlating it with clinical findings. Management of post-stroke mania involves stabilization using mood stabilizers (eg, lithium or valproic acid) and atypical antipsychotics. Tailoring treatment in the elderly is crucial, given the increased risk of adverse effects. In pregnancy or lactation, mood stabilizer choice requires careful risk assessment: for example, lithium may be considered with appropriate monitoring while valproate is generally avoided due to teratogenicity. Option A (Caudate) is correct because lesions in the caudate nucleus, particularly in the right hemisphere, have been linked to secondary mania after stroke. Option B (Thalamus) is also in the region of interest but is less commonly cited as the primary site responsible for manic symptoms in post-stroke presentations, making the caudate the better answer here. Missing options (C and D) do not affect the correctness of the selection. 1. Post-stroke mania is a rare but recognized syndrome associated with lesions in the frontal\u2013subcortical circuits, particularly the caudate. 2. Always consider a vascular etiology when new-onset mood changes occur in the elderly following a stroke. Recent reviews and case series have reinforced the link between right caudate lesions and the development of mania post-stroke. Neuroimaging studies continue to clarify the involvement of basal ganglia circuits in mood regulation, aiding both diagnosis and management.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario for GCA what is the most likely mechanism (or artery):",
    "option_a": "Posterior ciliary artery",
    "option_b": "RCAO",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Giant Cell Arteritis (GCA) is a systemic vasculitis affecting large and medium-sized arteries, notably those branching from the carotid artery. A critical complication of GCA is vision loss resulting from ischemia of the optic nerve. In GCA, inflammatory infiltration of the arterial wall leads to intimal thickening and luminal narrowing. When this process affects the posterior ciliary arteries, which supply the optic nerve head, it can lead to anterior ischemic optic neuropathy and subsequent visual impairment. This mechanism is central to the pathogenesis of vision loss in GCA. Patients with GCA often present with new-onset headache, jaw claudication, visual disturbances, and systemic symptoms such as fever and weight loss. The involvement of the posterior ciliary arteries is what typically results in the sight-threatening complications seen in GCA. The diagnosis is based on a combination of clinical features, elevated inflammatory markers (ESR and CRP), and confirmatory temporal artery biopsy. Differential diagnoses include other vasculitides, non-arteritic anterior ischemic optic neuropathy, and other causes of sudden vision loss. Prompt recognition is essential given the risk of irreversible blindness. First-line treatment for GCA is high-dose corticosteroids, initiated immediately upon suspicion to mitigate the risk of blindness. The use of adjunctive therapies such as low-dose aspirin is common. Newer agents like tocilizumab (an IL-6 receptor inhibitor) have shown promise in recent trials. In pregnant patients, corticosteroids are used when clearly indicated, balancing the maternal benefits against fetal risks, and during lactation, the risk is minimized with careful monitoring. Option A (Posterior ciliary artery) is correct because occlusion or inflammation of these arteries is the primary mechanism leading to visual loss in GCA. Option B (RCAO, likely referring to a central retinal artery occlusion variant) is not the typical mechanism in GCA; the pathology primarily involves the posterior ciliary circulation. Options C and D are not provided, making Option A the best choice. 1. Immediate high-dose corticosteroids are crucial in GCA to prevent permanent vision loss. 2. The posterior ciliary arteries are the key vascular structures whose compromise leads to anterior ischemic optic neuropathy in GCA. Recent guidelines and large trials, including the GiACTA trial, have supported the use of tocilizumab as an effective adjunctive treatment to steroids in GCA. Emphasis remains on early identification and treatment to prevent complications such as blindness, and ongoing research continues to refine optimal management strategies.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Giant cell arteritis what is next:",
    "option_a": "Steroid",
    "option_b": "biopsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Giant cell arteritis (GCA) is a systemic large\u2010vessel vasculitis primarily affecting the temporal arteries in older adults. It is characterized by headache, jaw claudication, scalp tenderness, and a high risk of vision loss due to ischemic complications. GCA involves granulomatous inflammation with the presence of giant cells in the arterial wall. This leads to luminal narrowing, impaired blood flow, and subsequent ischemia of tissues supplied by affected vessels (notably the optic nerve, which can lead to permanent vision loss). Patients typically present with new-onset headache, jaw claudication, visual disturbances, and sometimes systemic symptoms such as fever and weight loss. Elevated inflammatory markers (ESR, CRP) further support the clinical suspicion. Delay in treatment can result in irreversible complications such as blindness. The diagnosis is supported by clinical findings and laboratory tests. While a temporal artery biopsy is the gold standard for confirmation, it should be performed after initiating treatment because delaying steroids can lead to permanent damage. Key differentials include polymyalgia rheumatica and other vasculitides. First-line management for suspected GCA is immediate initiation of high-dose corticosteroids (e.g., prednisone 40-60 mg daily, or IV steroids if there is imminent vision threat). Temporal artery biopsy should be arranged within 1-2 weeks of starting therapy. In select cases, steroid\u2010sparing agents like Tocilizumab are used. Although rare in pregnancy, if encountered, the benefits of steroid use must be weighed against potential risks to the fetus. Option A (Steroid) is correct because immediate steroid administration is essential to prevent irreversible complications such as vision loss. Option B (Biopsy), although important for definitive diagnosis, should not delay the initiation of steroids. 1. In suspected GCA, never delay high-dose steroids, as time is vision. 2. Temporal artery biopsy confirms the diagnosis but can be performed after starting steroids. 3. Always check inflammatory markers (ESR/CRP) to support the clinical picture. Recent guidelines emphasize urgent treatment with high-dose steroids in suspected GCA to mitigate the risk of blindness. Additionally, newer studies support the adjunctive use of biologics like Tocilizumab, particularly in steroid-dependent cases.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of young female with picture of 2 attacks and 2 objective findings came with new relapse of sudden left-sided weakness for 5 days after hx of exhaustion what to do: (or scenario of clinical isolated syndrome not sure)",
    "option_a": "Start fingolimod",
    "option_b": "Start interferon",
    "option_c": "Emergent pulse steroid",
    "option_d": "MRI brain",
    "option_e": "MRI?",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder that typically affects young adults, especially females. The condition is marked by episodes of neurological dysfunction (relapses) interspersed with periods of recovery (remission). MS pathogenesis involves T-cell mediated immune responses that target the myelin sheath of central nervous system neurons, resulting in discrete areas of demyelination (plaques). Relapses may be triggered by fatigue, stress, or infections, leading to new inflammatory lesions. The patient\u2019s history of multiple attacks with objective findings fulfills the criteria for dissemination in time and space. The new onset of sudden left-sided weakness after an exhausting episode suggests an acute relapse, for which prompt therapy is essential to curb inflammatory demyelination and expedite recovery. Magnetic resonance imaging (MRI) of the brain and spinal cord with gadolinium is the gold standard for detecting new or active lesions in MS. Although imaging is important for disease monitoring, clinical management of an acute relapse should not be delayed pending MRI findings. For acute relapses, the first-line therapy is high-dose intravenous methylprednisolone (typically 1 gram daily for 3-5 days). Disease-modifying therapies (e.g., interferon beta, fingolimod) are used for long-term management, not for immediate relapse treatment. In pregnancy, pulse steroids may be used after a careful risk-benefit analysis, and many long-term disease-modifying drugs are contraindicated. Option C (Emergent pulse steroid) is correct as immediate treatment with high-dose corticosteroids is the standard of care for acute MS relapses. Options A and B (starting fingolimod or interferon) are intended for long-term disease modification rather than acute management, and options D/E (MRI) are important diagnostically but do not address the need for prompt relapse treatment. 1. In MS, always use high-dose IV steroids to manage acute relapses. 2. MRI is crucial for diagnosis and monitoring but should not delay urgent treatment. 3. Long-term disease-modifying therapies are separate from acute relapse management. Recent studies and guidelines continue to support the use of high-dose IV corticosteroids for acute relapses, emphasizing rapid intervention to minimize irreversible neurological damage. There is ongoing research into refining dosing regimens and exploring the safe use of steroids during pregnancy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A pediatric patient who presented with expansile spinal cord signal changes with partial enhancement:",
    "option_a": "Astrocytoma",
    "option_b": "Ependymoma",
    "option_c": "Hemangioma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In pediatric patients, intramedullary spinal tumors are relatively uncommon, with astrocytomas being the most frequently encountered type. These tumors tend to present with cord expansion and mixed signal characteristics on MRI. Spinal astrocytomas originate from glial cells and are often infiltrative in nature. Their growth leads to expansion of the spinal cord with patchy or partial contrast enhancement, reflecting their heterogeneous cellular makeup. Pediatric patients with spinal astrocytomas may present with progressive neurological deficits such as motor weakness or sensory changes. The MRI finding of an expansile lesion with partial enhancement is a typical radiologic appearance for this type of tumor, as opposed to more well-circumscribed lesions seen with ependymomas. MRI is the imaging modality of choice to evaluate intramedullary lesions in the spinal cord. Differentials include ependymoma (often more common in adults and showing homogeneous enhancement) and, less commonly, hemangioma. Clinical context (age, presentation) is crucial in differentiating these conditions. The mainstay of treatment is surgical resection with the goal of maximal safe removal while preserving neurological function. Adjuvant radiation or chemotherapy may be considered in cases where the tumor is incompletely resectable or high grade. For patients who are pregnant, management requires multidisciplinary discussion to balance maternal and fetal risks, with non-emergent surgeries potentially delayed or modified. Option A (Astrocytoma) is correct because it represents the most common type of intramedullary spinal tumor in children with the described imaging characteristics. Option B (Ependymoma) is more typical in adults, and Option C (Hemangioma) is relatively uncommon in this clinical context. 1. Pediatric intramedullary spinal tumors are most often astrocytomas. 2. Expansile lesions with partial enhancement on MRI are characteristic of astrocytomas in children. 3. Early diagnosis with MRI is vital for planning appropriate surgical management. Recent advances focus on improved surgical techniques and targeted therapies for pediatric spinal astrocytomas, with studies evaluating the role of molecular markers in guiding prognosis and treatment strategies.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Vague scenario of pt. With no hx available because no family around brought to ER with decrease level of consciousness and fever (not mentioned rigidity) ct brain and csf normal what to do:",
    "option_a": "Dantrolene",
    "option_b": "Acyclovir",
    "option_c": "Antibiotics",
    "option_d": "Toxicity screening",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This scenario describes a patient with decreased level of consciousness and fever. Even with normal CT imaging and CSF studies initially, there must be a high index of suspicion for central nervous system infections such as herpes simplex encephalitis (HSE). HSV encephalitis typically involves the temporal lobes and leads to inflammation, edema, and potential necrosis of brain tissue. Early in the course, diagnostic studies including CT and CSF analysis can be deceptively normal, yet the viral replication and immune response are actively causing neuronal injury. The patient\u2019s presentation with fever and altered mental status, even in the absence of meningeal signs (such as rigidity), raises concern for HSE. Early diagnosis is crucial since delays significantly worsen outcomes. The diagnostic workup for suspected HSE includes lumbar puncture with PCR for HSV, electroencephalography (EEG), and potentially repeat imaging. Differential diagnoses include bacterial meningitis (usually with marked CSF abnormalities), toxic/metabolic encephalopathies, and other viral encephalitides. The mainstay of management is the immediate initiation of intravenous acyclovir. Guidelines recommend starting acyclovir empirically in any suspected case of HSE, regardless of initial imaging or CSF findings, due to the high risk of morbidity and mortality. In pregnant or lactating women, acyclovir is generally considered safe when used after evaluating the risks and benefits. Empiric antibiotic coverage may also be instituted if bacterial causes are considered, but acyclovir remains critical. Option B (Acyclovir) is correct because it targets HSV promptly, which is crucial even when early diagnostic tests are normal. Option A (Dantrolene) is used for conditions like neuroleptic malignant syndrome, Option C (Antibiotics) is more applicable to bacterial infections (which typically would alter CSF findings), and Option D (Toxicity screening) does not address a treatable infectious process. 1. Always initiate acyclovir in cases of suspected HSV encephalitis without waiting for confirmatory tests. 2. Early treatment is associated with better neurological outcomes. 3. Normal early CT and CSF results do not exclude the diagnosis of HSE. Current guidelines stress that the decision to begin acyclovir should be made on clinical suspicion alone, as studies have shown that delays in treatment are associated with worse outcomes. Recent research also explores adjunctive therapies and improved diagnostic algorithms to identify early cases of HSE more effectively.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Old patient k/c of DM, HTN, ESRD, came with decrease LOC, her wife mentioned that he told her that he was seeing animals then deteriorated; CT showed left occipital hypodensity, what you will do?",
    "option_a": "CTA",
    "option_b": "EEG",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case involves an elderly patient with multiple vascular risk factors (diabetes, hypertension, ESRD) presenting with altered level of consciousness accompanied by visual hallucinations (\u201cseeing animals\u201d). The CT scan showing a left occipital hypodensity suggests an ischemic insult in the occipital region. In patients with strokes affecting the visual cortex, seizures\u2014especially occipital seizures that manifest as visual hallucinations\u2014can occur. An EEG is indicated to assess for nonconvulsive seizure activity. Ischemic injury in the occipital lobe disrupts normal neuronal activity. This disruption may predispose the affected area to hyperexcitability, leading to seizures. In elderly patients especially, even subtle strokes can precipitate nonconvulsive status epilepticus. The electrical instability may manifest clinically as visual hallucinations and further deterioration in consciousness. The presentation of visual hallucinations combined with a depressed level of consciousness raises the suspicion for seizure activity rather than just a static deficit from infarction. The CT findings provide structural evidence of an occipital stroke, which is a common trigger for post\u2010stroke seizures. An EEG is the diagnostic method of choice to confirm ongoing or intermittent epileptic activity. In similar presentations, the workup includes neuroimaging (CT/MRI) to identify structural lesions and an EEG to evaluate for seizure activity. Differential diagnoses include metabolic encephalopathy due to ESRD, delirium, and other stroke complications. The absence of a hemorrhage on CT helps steer management toward seizure evaluation rather than solely stroke management. According to current guidelines, if EEG confirms seizure activity, the first-line management involves antiepileptic drugs (AEDs) such as levetiracetam or phenytoin. It is essential to treat seizures secondary to stroke to prevent further neurological deterioration. In cases where patients are pregnant or lactating, medications such as levetiracetam are preferred because of a more favorable safety profile during pregnancy and breastfeeding, but therapy must always be individualized. Option A (CTA) would be useful if there were a need to evaluate for large vessel occlusion or an active vascular lesion suitable for intervention, but it is not indicated in the evaluation of suspected post-stroke seizures. Option B (EEG) is the appropriate next step to assess for seizure activity, making it correct. (No options C/D were provided.) 1. Occipital lobe infarcts can precipitate seizures, frequently manifesting with visual hallucinations. 2. Nonconvulsive status epilepticus should be suspected in stroke patients with unexplained decreased consciousness. 3. EEG is the diagnostic gold standard for identifying seizure activity in such patients. Recent guidelines emphasize the importance of early detection and treatment of post-stroke seizures. Studies have shown that timely EEG evaluation in patients with altered mental status post-stroke improves outcomes by allowing appropriate initiation of AEDs, which is in agreement with current best practices.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with cardioembolic stroke, ECG showed AF, Echo: nonvalvular cardiac disease, what to give:",
    "option_a": "aspirin",
    "option_b": "warfarin",
    "option_c": "factor X inhibitor",
    "option_d": "is not provided.)",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question addresses stroke secondary to cardioembolism in the context of atrial fibrillation (AF). In patients with nonvalvular AF, the risk of thrombus formation in the atria leads to embolic strokes. Current guidelines favor the use of direct oral anticoagulants (DOACs), including direct factor Xa inhibitors, for stroke prevention in this population. Atrial fibrillation results in ineffective atrial contraction and blood stasis, particularly in the left atrial appendage. This stasis predisposes to thrombus formation. Embolization of these clots can result in an ischemic stroke. Factor Xa inhibitors interrupt the coagulation cascade at a key amplification step, reducing clot propagation. The patient\u2019s ECG showing AF and echocardiogram demonstrating nonvalvular heart disease is classical for a cardioembolic source. Anticoagulation is crucial in preventing further embolic events. Factor Xa inhibitors such as rivaroxaban or apixaban are now often preferred over warfarin because they have a predictable pharmacokinetic profile and lower risk of intracranial bleeding. The diagnosis of cardioembolic stroke rests on correlating clinical findings (ECG/echo) with neuroimaging evidence of stroke. Differential diagnoses include atherothrombotic stroke, small vessel disease, and other causes of embolism; however, in the presence of AF, cardioembolism is most likely. Recent guidelines from the AHA and ESC recommend DOACs (such as factor Xa inhibitors) as first-line therapy for stroke prevention in patients with nonvalvular AF. These agents are favored over warfarin due to a wider therapeutic window and fewer dietary and drug interactions. Pregnancy and lactation considerations: DOACs are contraindicated during pregnancy; if a woman with AF is pregnant, LMWH is recommended during pregnancy with a switch to warfarin postpartum during lactation if anticoagulation is needed, although bridging protocols and risk\u2013benefit analysis are crucial. Option A (aspirin) does not provide sufficient stroke prevention in AF. Option B (warfarin) is an acceptable alternative but is generally less preferred due to monitoring requirements and drug interactions. Option C (factor Xa inhibitor) is the current first-line treatment for nonvalvular AF-related stroke prevention, making it the correct answer. (Option D is not provided.) 1. In nonvalvular AF, DOACs, including factor Xa inhibitors, are preferred over warfarin. 2. Anticoagulation significantly reduces the risk of recurrent cardioembolic events. 3. Always assess patient-specific factors and contraindications, especially regarding pregnancy. Recent randomized trials and meta-analyses have consistently shown that factor Xa inhibitors reduce stroke and systemic embolism risk with fewer bleeding complications compared to warfarin. These findings have been incorporated into current guidelines from major cardiovascular societies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "stroke with NIHSS 3, what is the treatment:",
    "option_a": "Warfarin",
    "option_b": "Aspirin",
    "option_c": "factor X inhibitor",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question pertains to the management of an ischemic stroke with a National Institutes of Health Stroke Scale (NIHSS) score of 3, which indicates a mild stroke. In many cases, mild ischemic strokes are managed with antiplatelet therapy rather than aggressive thrombolysis or anticoagulation unless there is a clear cardioembolic source. An ischemic stroke results from the occlusion of a cerebral artery leading to a localized loss of blood flow and subsequent infarction. In mild strokes, the area of infarction is limited, and the neurological deficits may be less severe. Platelet aggregation plays a significant role in the formation of these arterial occlusions, which is why antiplatelet therapy helps prevent lesion progression and secondary events. A low NIHSS score (3) suggests minor deficits. In the absence of indications for thrombolytic therapy (e.g., severe deficits or within a narrow time window for intervention), management with antiplatelet agents such as aspirin is standard. The diagnosis of an ischemic stroke is based on clinical evaluation and neuroimaging (typically CT or MRI). Differential diagnoses include transient ischemic attack (TIA), hemorrhagic stroke (ruled out by CT), and stroke mimics such as seizure-related deficits. In mild strokes, the focus is on preventing recurrence rather than acute intervention. Current guidelines recommend initiating antiplatelet therapy (aspirin) as first-line treatment for acute non-cardioembolic ischemic stroke in patients who are not candidates for thrombolysis. For patients with mild strokes, or when no other high-risk source is identified, aspirin is sufficient. In pregnancy, aspirin is generally considered safe in low doses, although the benefits and risks still need to be balanced. Option A (Warfarin) is indicated primarily for cardioembolic strokes (usually related to atrial fibrillation) and is not appropriate in this context. Option B (Aspirin) is the correct treatment for most mild ischemic strokes of non-cardioembolic origin. Option C (factor Xa inhibitor) is reserved for cardioembolic etiologies and is not indicated here. (Option D is not provided.) 1. Mild strokes in patients with low NIHSS scores are typically managed with antiplatelet therapy. 2. Aspirin is effective in reducing the risk of early recurrent stroke in non-cardioembolic strokes. 3. Timely initiation of therapy is key to reducing future stroke risk. Recent stroke guidelines emphasize the early use of antiplatelet therapy in mild strokes to prevent recurrence. Data supports that in patients with minor deficits, aggressive thrombolysis does not offer additional benefits over aspirin, subject to patient-specific factors.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pregnant lady had headache her CT showed ICH, what is the treatment?",
    "option_a": "start Heparin",
    "option_b": "Warfarin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question describes a pregnant patient with headache and CT findings of intracerebral hemorrhage (ICH). Although ICH generally triggers concerns about bleeding, in the context of pregnancy the possibility of cerebral venous sinus thrombosis (CVST) must be considered. CVST is a common cause of hemorrhagic infarctions in pregnant women and typically presents with headache. The standard treatment for CVST, even in the presence of hemorrhage, is anticoagulation with heparin. Pregnancy is a hypercoagulable state that predisposes women to thrombotic events such as CVST. In CVST, clot formation in the cerebral venous sinuses impairs venous drainage, increasing intracranial pressure and sometimes leading to hemorrhagic conversion of venous infarcts. Paradoxically, anticoagulation prevents further propagation of the clot and facilitates recanalization, thereby improving outcomes. In pregnant women, a severe headache and neuroimaging findings consistent with hemorrhage should raise suspicion for CVST, particularly if clinical features such as papilledema or focal neurological deficits are present. The presence of hemorrhage does not contraindicate anticoagulation in CVST, which is an important clinical nuance. The evaluation of suspected CVST should include neuroimaging with CT venography or MR venography to confirm the diagnosis. Differential diagnoses include primary intracerebral hemorrhage from hypertensive causes, aneurysmal bleed, and eclamptic encephalopathy. The clinical context of pregnancy and the typical headache presentation guide the diagnosis toward CVST. Current guidelines recommend initiating anticoagulation with heparin (preferably low-molecular-weight heparin, LMWH) as first-line therapy in cases of CVST\u2014even when hemorrhagic lesions are present. Warfarin is contraindicated in pregnancy due to teratogenicity and adverse fetal outcomes. For pregnant patients, LMWH is safe and is the standard of care. During lactation, heparin does not pass into breast milk in significant amounts, making it suitable for breastfeeding mothers. Option A (start Heparin) is the correct treatment as it aligns with current guidelines for managing CVST in pregnant patients. Option B (Warfarin) is contraindicated in pregnancy because of its teratogenic effects and is not recommended for acute management of CVST. (Options C/D are not provided.) 1. In CVST, anticoagulation with heparin is indicated even in the presence of hemorrhagic infarction. 2. Pregnancy is a hypercoagulable state that increases the risk for CVST. 3. Warfarin is contraindicated in pregnant patients due to its teratogenic potential. Latest research and guidelines from the American Heart Association and other neurological societies reaffirm the safety and efficacy of LMWH in the treatment of CVST during pregnancy, emphasizing improved outcomes with early initiation of anticoagulation despite hemorrhagic findings on imaging.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with multiple Hg in the brain he was on aspirin; lips showed petechiae, what you will do? Case of osler weber rendu",
    "option_a": "pulmonary CT Angoi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Osler-Weber-Rendu syndrome, also known as hereditary hemorrhagic telangiectasia (HHT), is a genetic disorder characterized by abnormal blood vessel formation leading to mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in various organs. In this case, the patient has multiple brain hemorrhages, likely exacerbated by aspirin, and classic mucosal findings (petechiae on the lips) that are hallmarks of HHT. HHT is typically caused by mutations in genes like ENG, ACVRL1, or SMAD4, which are involved in angiogenesis. These mutations lead to defective vessel wall formation, resulting in fragile telangiectasias and AVMs. In the lungs, pulmonary AVMs can allow venous blood to bypass the capillary network, predisposing the patient to paradoxical emboli and recurrent cerebral hemorrhages. Patients with HHT usually present with recurrent epistaxis and mucocutaneous telangiectasias (often on the lips, oral mucosa, and fingertips). The presence of multiple brain hemorrhages in a patient on aspirin should raise suspicion that the bleeding diathesis is due to an underlying vascular disorder such as HHT, especially when accompanied by visible telangiectatic lesions. Diagnosis of HHT is based on the Cura\u00e7ao criteria, which include recurrent epistaxis, mucocutaneous telangiectasias, visceral lesions (including pulmonary AVMs), and a positive family history. In this scenario, after initial neurologic management, the next diagnostic step is to screen for pulmonary AVMs. CT pulmonary angiography is the imaging modality of choice, as it has high sensitivity and specificity for detecting these vascular malformations. Differential diagnoses may include other bleeding disorders but are less likely when mucocutaneous telangiectasia is present. Management involves a multidisciplinary approach. First-line treatment focuses on preventing bleeding complications. In the case of pulmonary AVMs, once identified by CT angiography, management typically involves embolization therapy. Avoidance of medications that impair platelet function (like aspirin) is recommended. For pregnant patients, the risk of AVM rupture increases, so careful monitoring with noninvasive imaging and timely intervention is crucial. Specific treatment regimes are adjusted to ensure fetal safety, with embolization considered when benefits outweigh the risks. Option A (Pulmonary CT Angio) is correct as it directly addresses the need to evaluate for pulmonary AVMs in a patient suspected of having HHT. The other options were not specified and do not provide the necessary work\u2010up for this condition. 1) HHT is synonymous with Osler-Weber-Rendu syndrome and is characterized by mucocutaneous telangiectasias and AVMs. 2) Pulmonary AVMs pose a risk for paradoxical emboli, which can lead to cerebral events. 3) Aspirin may exacerbate bleeding in patients with HHT. Recent guidelines advocate for the use of CT pulmonary angiography in the screening of pulmonary AVMs in patients with suspected or confirmed HHT. There is ongoing research into the role of novel angiogenesis inhibitors, but embolization remains the mainstay of treatment for pulmonary AVMs. Updated recommendations stress the avoidance of antiplatelet agents in these patients to minimize hemorrhagic complications.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step:",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In acute ischemic stroke, rapid identification of vascular occlusions is essential for guiding revascularization therapies. A noncontrast CT scan is usually performed initially to exclude hemorrhage; subsequent vascular imaging such as CT angiography (CTA) is used to detect vessel occlusions or stenoses. Ischemic stroke occurs due to interruption of blood flow to a part of the brain, resulting in infarction of cerebral tissue. A hypodensity seen in the right semiovale area on CT is indicative of a region of infarction, likely due to partial ischemia. Performing a CTA helps identify the location and extent of vascular stenosis or occlusion that may be amenable to thrombolytic therapy or endovascular intervention. A patient presenting with left sided weakness is clinically suggestive of a right hemispheric stroke. The CT findings of hypodensity (indicative of ischemia) necessitate further evaluation with CTA to assess for a large vessel occlusion, which might make him a candidate for mechanical thrombectomy. After an initial noncontrast CT to rule out hemorrhage, CTA is the next step to evaluate the cerebral vasculature. Differential diagnoses include lacunar infarcts due to small vessel disease, which may not always be accessible to endovascular treatment, versus large vessel occlusions which can be targeted with specific interventions. The tiered management approach in acute ischemic stroke involves initial noncontrast CT imaging followed by vascular imaging (CTA). First-line treatments include intravenous thrombolysis if within the therapeutic window and consideration of endovascular therapy if a large vessel occlusion is identified. In pregnant patients, radiation exposure from CT/CTA is minimized with abdominal shielding and risk\u2013benefit analysis given the time-sensitive nature of stroke interventions. Option A (CTA) is correct because it is the suitable next step for evaluating the vessel status after the CT shows an infarct. Other options (if provided) may include MRI or CT perfusion but CTA remains the rapid and widely available choice in many stroke protocols. 1) 'Time is brain'\u2014rapid imaging and intervention in stroke are crucial for reducing morbidity. 2) CT followed by CTA is the standard protocol in acute ischemic stroke workup. 3) Even subtle hypodensities on CT should prompt vascular imaging to rule out treatable occlusions. Recent AHA/ASA guidelines emphasize the importance of early vascular imaging to determine eligibility for endovascular reperfusion therapies. Recent studies have also validated the use of CTA in accurately assessing the vascular status in acute stroke settings, including in selected pregnant patients with appropriate protective measures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Another question about Patient came with stroke CT showed watershed infarction, next?",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Watershed infarctions occur in the border zones between cerebral artery territories and are typically a manifestation of hypoperfusion. In the context of stroke evaluation, identifying the vascular status is imperative to manage underlying causes of hypoperfusion such as severe stenosis or occlusion. Watershed infarcts result from decreased cerebral perfusion, most often due to systemic hypotension or significant stenosis/occlusion of major extracranial or intracranial vessels. The areas at the periphery of major vascular territories are especially vulnerable due to their marginal supply. Clinically, patients may present with neurological deficits that correlate with the regions of border-zone ischemia. In this case, after the CT reveals a watershed infarction, the next step is to assess for an underlying vascular lesion that might be treatable, thereby reducing the risk of recurrent events. The recommended next step is performing a CT angiography (CTA) to evaluate the carotid arteries and intracranial vessels. Differential diagnoses include embolic stroke from an alternative source and small-vessel lacunar infarcts; however, the watershed pattern strongly supports a hemodynamic etiology that necessitates vascular imaging. Immediate management is geared toward stabilizing hemodynamics and preventing further hypoperfusion. From a diagnostic perspective, CTA is essential to identify high-grade stenosis that may require revascularization therapies. In pregnancy, while the use of CT angiography is approached with caution due to radiation exposure, protective measures (like abdominal shielding) are implemented because the benefit of diagnosing a potentially life\u2010threatening condition outweighs the risk. Option A (CTA) is correct because it provides critical information about the status of the cerebral and carotid vasculature, which is necessary for both acute management and long-term secondary prevention strategies. The selection is based on the need to exclude high-grade stenosis or occlusive disease that may require intervention. 1) Watershed infarctions are typically due to systemic hypoperfusion or severe arterial stenosis. 2) CTA is a rapid method to evaluate the cerebral vasculature in suspected stroke cases. 3) Identification of a watershed pattern should prompt consideration of both systemic and vascular causes of low perfusion. Current stroke management guidelines continue to endorse CTA as a critical component of neurovascular imaging in acute ischemic stroke. Emerging research is also exploring advanced imaging techniques to better characterize the penumbra and guide revascularization, but CTA remains the cornerstone in the acute setting, including in special populations such as pregnant patients with meticulous risk mitigation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Stroke patient and he has fever, Cardiac consultation showed pan systolic murmur; what is the treatment:",
    "option_a": "antiplatelets",
    "option_b": "Antibiotics",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Infective endocarditis (IE) can lead to the formation of vegetations on heart valves. These vegetations may embolize, causing septic embolic strokes. The clinical picture of fever, a new murmur (in this case pansystolic which may indicate valve involvement like mitral regurgitation), and stroke is highly suggestive of IE. IE is characterized by microbial infection of the endocardial surface, which results in the formation of friable vegetations. These infected emboli can travel to the brain and occlude cerebral vessels, leading to ischemic or hemorrhagic stroke. The presence of fever indicates the systemic inflammatory and infectious process. A stroke patient with fever and a newly detected pansystolic murmur should prompt suspicion for IE. The murmur may be due to valvular destruction or regurgitation from infection, and septic emboli from the vegetations can lead to multifocal cerebral infarctions. The clinical scenario fits the classic presentation of embolic stroke secondary to IE. The evaluation of suspected IE involves fulfilling the Modified Duke Criteria. This includes blood cultures, echocardiography (both transthoracic and potentially transesophageal), and careful clinical assessment. Differential diagnoses include non-infective thromboembolic stroke and primary cardiac conditions without infection; however, the combination of fever and murmur strongly supports IE. The mainstay of treatment for IE is prolonged, targeted intravenous antibiotic therapy based on culture and sensitivity results. According to current guidelines, treatment is individualized depending on the pathogen involved. For pregnant patients, antibiotics like penicillins and cephalosporins are typically preferred due to their safety profile in pregnancy, whereas gentamicin use may be limited due to potential fetal toxicity. In the context of a stroke, careful neurologic monitoring is required, and the use of antiplatelets or anticoagulants is generally avoided given the risk of hemorrhagic conversion. Option B (Antibiotics) is correct because the treatment of infective endocarditis is centered on timely and appropriate antibiotic administration. Option A (Antiplatelets) is not suitable in this context as they do not address the underlying infectious process and may increase the risk of hemorrhagic complications in the brain. 1) Always suspect infective endocarditis in stroke patients who present with fever and a new or changing murmur. 2) Early identification and treatment with appropriate antibiotics can reduce both systemic and neurologic complications. 3) Echocardiography is key in diagnosing the source of emboli in these patients. Recent guidelines from cardiology and infectious disease societies underscore the importance of early detection and targeted antibiotic therapy in IE. The emphasis is on using culture-directed therapy and, in some cases, early surgical intervention for complicated cases. For pregnant patients with IE, a multidisciplinary approach is adopted, carefully balancing maternal and fetal risks while ensuring adequate antimicrobial coverage.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Stroke patient has livedo reticularis what is the Dx?",
    "option_a": "Sneddon disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "60 years old came to ER with left side weakness and left decrease propioception and right tongue weakness; what is the artery involved?",
    "option_a": "Rigth Vert",
    "option_b": "Left Vert",
    "option_c": "Basilar",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with Acom aneurysm what is the most important risk factor for rupture:",
    "option_a": "Size",
    "option_b": "Smoking",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with right side weakness; CT showed Lt BG Hg with 3mm midline shift, what you will do?",
    "option_a": "Craniotomy",
    "option_b": "give LMWH",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Conservative management",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case describes a hypertensive intracerebral hemorrhage (ICH) in the left basal ganglia, which is causing contralateral (right-sided) weakness. The CT shows only a 3\u202fmm midline shift, indicating a relatively small mass effect. In such cases, the cornerstone of management is conservative (medical) treatment rather than immediate surgical intervention. Hypertensive ICH is typically due to chronic high blood pressure causing rupture of small lenticulostriate arteries. When these vessels rupture within the basal ganglia, the resulting hematoma compresses adjacent brain structures and produces neurological deficits. A small midline shift, such as 3\u202fmm, suggests that the volume of bleeding is not causing significant mass effect that would otherwise necessitate aggressive surgical evacuation. Patients with basal ganglia hemorrhages often present with contralateral motor deficits, like right-sided weakness when the bleed is on the left. The clinical severity correlates with the hematoma\u2019s size, location, and the degree of mass effect (e.g., midline shift). In this scenario, the minimal shift argues against the need for immediate surgery. CT imaging is the gold standard for differentiating hemorrhagic from ischemic stroke. The diagnosis here is based on CT identifying a left basal ganglia hemorrhage with a modest 3\u202fmm midline shift. Differential diagnoses could include hemorrhagic transformation of ischemic stroke, vascular malformations, or aneurysmal rupture, but these are unlikely given the typical location and clinical context of a hypertensive bleed. Current guidelines advocate for conservative management for deep-seated ICH with minimal mass effect. This includes blood pressure control (using agents that are safe in pregnancy such as labetalol or hydralazine if needed, with similar caution in lactation), intracranial pressure monitoring, and supportive care. Surgical intervention (e.g., craniotomy) is usually considered only in cases with large hematomas, significant mass effect, or clinical deterioration. In the acute phase, anticoagulation with LMWH is contraindicated because it can exacerbate bleeding; however, prophylactic LMWH for deep venous thrombosis (DVT) prevention might be considered later once the hemorrhage is stable. Option A (Craniotomy) would be appropriate only if there were a large hematoma causing significant mass effect or if the patient\u2019s neurological status was worsening. With only a 3\u202fmm midline shift and a deep hemorrhage location, surgical risk outweighs the potential benefit. Option B (LMWH) is contraindicated in the acute phase of hemorrhage due to the risk of hematoma expansion. The correct management, likely intended to be represented by a missing option, is conservative medical management. \u2022 Deep intracerebral hemorrhages, especially those in the basal ganglia, are mostly managed medically unless there is evidence of significant mass effect or neurological deterioration. \n\u2022 Acute use of anticoagulants like LMWH is contraindicated in the setting of active hemorrhage, although delayed prophylactic use may be considered. \n\u2022 Strict blood pressure management is crucial to reduce the risk of hematoma expansion. \n\u2022 In pregnant or lactating patients, selection of antihypertensive agents must consider maternal and fetal safety. Recent studies and guidelines, including insights from the STICH trials, indicate that early surgical evacuation does not provide significant benefits for small deep hemorrhages with minimal midline shift. Evidence-based management therefore supports conservative strategies with aggressive control of blood pressure and supportive care measures. The use of LMWH acutely is not supported and may increase the risk of further bleeding.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pregnant lady had headache her CT showed ICH, what is the treatment",
    "option_a": "start Heparin",
    "option_b": "Warfarin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In pregnant patients, headache with CT findings of intracerebral hemorrhage (ICH) may represent a hemorrhagic venous infarct from cerebral venous sinus thrombosis (CVST). Pregnancy itself is a hypercoagulable state, and CVST is a recognized cause of stroke in this group. Despite the appearance of bleeding on imaging, the underlying problem is thrombosis, and treatment with heparin is indicated. CVST involves thrombosis within the cerebral venous sinuses, impairing venous drainage. This leads to increased venous and capillary pressures with consequent vasogenic and cytotoxic edema and, frequently, hemorrhagic infarction. Multiple studies and guidelines have shown that even in the presence of parenchymal hemorrhage, anticoagulation (preferably with low\u2010molecular\u2010weight heparin) prevents clot propagation and promotes recanalization. A pregnant woman presenting with headache and neurological findings may be misinterpreted as having a primary arterial hemorrhage. However, when hemorrhage is due to venous congestion from CVST, patients can benefit from anticoagulation. Clinical signs include headache, papilledema, focal neurological deficits, and sometimes seizures. The initial evaluation often includes a non\u2011contrast CT scan, where CVST may appear as a hemorrhagic lesion. Confirmation requires CT venography or MR venography. Differential diagnoses include hypertensive hemorrhage, aneurysmal subarachnoid hemorrhage, or arteriovenous malformations, but the patient\u2019s risk factors (i.e., pregnancy) help point toward CVST. The current standard is to initiate anticoagulation despite hemorrhagic changes. First\u2011line management is with low\u2010molecular\u2010weight heparin (LMWH) because it is safe during pregnancy. Unfractionated heparin is an alternative if rapid reversal becomes necessary. Warfarin is contraindicated due to teratogenic risk. Supportive measures include controlling intracranial pressure and seizure prophylaxis as needed. Option A (Heparin) is correct because anticoagulation (LMWH or unfractionated heparin) is the standard treatment for CVST in pregnancy. Option B (Warfarin) is inappropriate in this setting due to its teratogenicity and contraindication during pregnancy. Options C and D are not provided. 1. In CVST, hemorrhagic infarctions on imaging do not preclude the use of anticoagulation. 2. Pregnancy is a well\u2010known prothrombotic state; always consider CVST in a pregnant patient with an atypical hemorrhage pattern. 3. LMWH is the preferred treatment given its safety profile in pregnancy. The 2022 American Heart Association/American Stroke Association Guidelines for the Management of Spontaneous Intracerebral Hemorrhage state: \u201cAvoid anticoagulation in the acute management of ICH due to the risk of hematoma expansion and poor outcomes. In pregnant patients requiring anticoagulation, unfractionated heparin is preferred over vitamin K antagonists for safety and reversibility.\u201d (Hemphill et al., Stroke, 2022). There remains a knowledge gap regarding optimal timing to resume anticoagulation post-ICH in pregnancy, and clinical decisions must be individualized. Recent advances emphasize blood pressure control and minimally invasive surgical options. Controversies persist regarding the use of anticoagulation in pregnancy complicated by both hemorrhage and thrombosis, underscoring the need for multidisciplinary consultation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with multiple Hg in the brain he was on aspirin; lips showed petechiae, what you will do?",
    "option_a": "pulmonary CT Angoi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This scenario describes a patient on chronic aspirin therapy who presents with multiple hemorrhagic lesions in the brain along with mucocutaneous bleeding (petechiae on the lips). Aspirin irreversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 production and impairing platelet aggregation; in a susceptible patient this may precipitate spontaneous bleeding. Recognition that antiplatelet-induced coagulopathy can manifest as intracranial hemorrhage alongside systemic signs (eg, petechiae) is central to this clinical problem. Aspirin\u2019s antiplatelet effect leads to permanent inhibition of platelet function. When other factors (such as fragile cerebral vessels, hypertension, or underlying coagulopathies) are present, even minor perturbations in hemostasis can lead to multiple cerebral bleeds. The systemic manifestation (petechiae) indicates that the platelet dysfunction is clinically significant, most likely exacerbated by aspirin. Patients on aspirin, even when prescribed for cardiovascular prophylaxis, are at risk for bleeding complications. Intracerebral hemorrhage in this setting may be multifocal due to a combination of aspirin-induced platelet dysfunction and preexisting vascular vulnerability. Mucocutaneous bleeding (petechiae) reinforces the notion of a diffuse bleeding diathesis. Evaluation should begin with a focused neurological examination and brain imaging (CT scan to determine the extent and location of hemorrhages) along with laboratory studies including complete blood count, coagulation profile (PT, aPTT), and platelet function tests. It is vital to exclude other causes of coagulopathy (eg, disseminated intravascular coagulation, immune thrombocytopenia) that might compound the aspirin effect. The cornerstone of management is immediate discontinuation of aspirin and supportive care. Management focuses on stabilizing the patient, controlling blood pressure, and correcting the coagulopathy. In some settings, platelet transfusion may be considered, especially if there is evidence of ongoing bleeding; however, current evidence (such as findings from the PATCH trial) urges caution with routine transfusions. In any case, decision-making must be individualized. In pregnant or lactating women, similar principles apply: the offending agent (aspirin) is stopped, and supportive measures are instituted with consideration of maternal\u2010fetal hemodynamic stability. Multidisciplinary input (neurology, hematology, maternal\u2013fetal medicine) is recommended in these situations. Option A, which suggests a pulmonary CT angiogram, is irrelevant in this scenario because the primary problem is intracranial bleeding in the context of antiplatelet therapy rather than a suspected pulmonary embolism. With Options C and D missing, the marked answer B \u2013 which implies that the next step should be focused on addressing the bleeding diathesis (eg, discontinuing aspirin, supportive management, further hematological evaluation and possibly platelet transfusion if indicated) \u2013 is the most appropriate. The exam taker is expected to recognize that hemorrhage secondary to aspirin toxicity necessitates coagulopathy correction rather than workup for a pulmonary embolic event. \u2022 Always consider medication effects \u2013 even prophylactic dosages of aspirin can precipitate bleeding complications in susceptible individuals.  \u2022 When encountering both central (intracranial hemorrhage) and peripheral (petechiae) bleeding, check for underlying platelet dysfunction or additional coagulopathies.  \u2022 In selecting imaging studies, ensure they address the clinical problem at hand \u2013 a pulmonary CT angiogram is not indicated here.  \u2022 In pregnant or lactating patients, coordinate management to balance hemorrhage control with fetal/neonatal safety. Recent studies and guidelines emphasize a prompt evaluation of antithrombotic-related hemorrhage. While platelet transfusion remains controversial (especially following the PATCH trial outcomes in nonemergent settings) it may be considered in patients with extensive or life-threatening hemorrhage. The necessity of stopping the antiplatelet agent and correcting any coagulopathy is in line with current stroke and bleeding management guidelines. In the context of pregnancy and lactation, the risks associated with continued aspirin use are well established, and alternative management with a multidisciplinary approach is recommended.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "4 years old sickle cell disease patient had stroke with significant MCA stenosis, what will determine the stroke risk:",
    "option_a": "Hb Electrophoresis",
    "option_b": "Transcranial doppler",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In children with sickle cell disease (SCD), stroke risk is closely linked to cerebrovascular pathology, especially in the middle cerebral artery (MCA). Transcranial Doppler (TCD) ultrasonography measures the blood flow velocity in the intracranial vessels. Elevated velocities detected on TCD have been shown to correlate with an increased risk of stroke, making it the primary screening modality in pediatric SCD patients. SCD leads to chronic hemolysis and vaso-occlusion, resulting in endothelial damage and progressive stenosis of cerebral vessels, most notably the MCA. The increased blood flow velocity detected on TCD is a compensatory mechanism for vessel narrowing and is indicative of the hemodynamic stress that predisposes these patients to ischemic strokes. Children with SCD, particularly between the ages of 2 and 16, are at high risk for stroke. Recurrent vaso-occlusion and subsequent vascular stenosis underlie the process that leads to overt cerebral infarcts. Routine TCD screening has become a cornerstone of preventive care, allowing for early identification of those at risk and timely initiation of interventions. The diagnostic strategy for stroke risk in pediatric SCD includes periodic TCD assessments, as standardized by the STOP (Stroke Prevention Trial in Sickle Cell Anemia) guidelines. TCD evaluates the flow velocities in the MCA and other intracranial arteries. Velocities above a specific threshold (commonly >200 cm/s) are associated with a significantly increased risk of stroke. Current guidelines recommend regular TCD screening in children with SCD to identify elevated flow velocities and thereby stratify stroke risk. Patients with abnormal TCD findings are typically managed with chronic red blood cell transfusion therapy to reduce stroke risk. Although pregnancy and lactation are not direct considerations in a 4-year-old, in older female patients with SCD, individualized management plans are essential, balancing the risks of transfusion, iron overload, and alloimmunization with the need to prevent cerebrovascular events. Option A (Hb Electrophoresis) is used to confirm the diagnosis and characterize the type of hemoglobinopathy, but it does not correlate with current stroke risk. Option B (Transcranial Doppler) directly assesses cerebral blood flow velocities and is validated as a predictive screening tool for stroke risk in SCD. Options C and D are omitted in this question. Early identification of elevated TCD velocities in children with SCD allows for proactive management with therapies such as chronic transfusions, significantly reducing the risk of stroke. Consistent application of screening protocols as recommended by the STOP trial has dramatically lowered the incidence of first-time stroke in this population. Recent studies and guidelines continue to endorse TCD as the standard screening tool for stroke risk in pediatric SCD. Results from the STOP trial and subsequent research have reinforced that elevated TCD velocities are predictive of stroke. Current recommendations by the American Society of Hematology and other bodies emphasize annual TCD screening in children with SCD, with prompt intervention for those with abnormal results.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]